🏛️ Verified NIH Record • Updated 2026-08-13
Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors (NCT06635785)
🟢 Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic Sponsor: OncoC4, Inc.
🩺 Plain-English Summary (8th-Grade Level)
BIPAVE-001 is a Phase 1-2 study for evaluating the safety, pharmacokinetics (PK), and efficacy of AI-081 in solid tumors.
Who can join: Review the eligibility criteria below.
Location: University of Alabama at Birmingham — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (21 Sites)
- University of Alabama at Birmingham — Birmingham, Alabama
- Highlands Oncology Group — Springdale, Arkansas
- MedStar Georgetown University Hospital — Washington D.C., District of Columbia
- University of Florida UF Health Cancer Center — Gainesville, Florida
- Memorial Healthcare System — Hollywood, Florida
- Ocala Oncology Center PL DBA Florida Cancer Affiliates — Ocala, Florida
- AdventHealth Cancer Institute — Orlando, Florida
- Northwestern University — Chicago, Illinois
- Norton Cancer Center — Louisville, Kentucky
- Dana-Farber Cancer Institute — Boston, Massachusetts
- University of Michigan Rogel Cancer Center — Ann Arbor, Michigan
- Henry Ford Health — Detroit, Michigan
- The Tisch Cancer Institute, Mount Sinai Medical Center — New York, New York
- University of North Carolina at Chapel Hill Cancer Center — Chapel Hill, North Carolina
- Duke University Medical Center - Duke Cancer Center — Durham, North Carolina
- Novant Health Cancer Institute — Winston-Salem, North Carolina
- The Ohio State University James Cancer Center — Columbus, Ohio
- Prisma Health — Greenville, South Carolina
- MD Anderson Cancer Center — Houston, Texas
- University of Texas Health San Antonio Mays Cancer Center — San Antonio, Texas
- University of Utah Huntsman Cancer Institute — Salt Lake City, Utah
📞 Contact the Study Coordinator
Phone: (202) 751-6823
Email: pzheng@oncoc4.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Advanced Solid Tumor
- Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression — Iowa City, Iowa
- A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors — Glendale, California
- QTX3046 in Patients With KRAS G12D Mutations — Grand Rapids, Michigan
- A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors — Houston, Texas
- First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer — Fullerton, California
- A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors — San Antonio, Texas
Explore by condition: All Advanced Solid Tumor clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.